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Human meconium was found to contain two kinds of gangliosides with the same carbohydrate s quences belonging to 
the lacto-series. They were detected by TLC-immunostaining with monoclonal ntibodies directed to the NeuAcct2-6Gal 
and Lc4Cer structures. One of these two gangliosides, a major one, which migrated on TLC to a position below that 
of standard IVaNeuAcnLc4Cer f om human erythrocytes, reacted with the antibody to NeuAca2~Gal. The other minor 
one, which migrated on TLC to a position corresponding to standard IVaNeuAcnLc4Cer, was detected with the antibody 
to Lc4Cer only when the plate, on which the individual gangliosides were separated, was subjected to prior treatment 
with Vibrio cholerae sialidase. The structures of the gangliosides, each identified by means of permethylation a alysis 
and enzyme treatment after isolation with antibody monitoring, were shown to be IV~NeuAcnLc4Cer for the former and 
IV3NeuAcLc4Cer for the latter, indicating that the lacto-series type 2 (nLc4Cer) and 1 (Lc4Cer) chains are sialylated at 
different linkages, ct2-6 and ct2-3, respectively. IV6NeuAcLc4Cer and IVaNeuAcnLc4Cer were not detected, even in trace 
amounts, on TLC-immunostaining with the monoclonal antibodies. The concentrations of IV6NeuAcnLc4Cer and 
IVaNeuAcLc4Cer were 448 and 18 nmol/g dry wt of human meconium. 
Lacto-series ganglioside; Monoclonal antibody 
1. INTRODUCTION 
Controlled glycosphingolipid synthesis occur- 
ring during germinal proliferation, differentiation 
and morphogenesis indicates the existence of a 
program believed to be quite closely concerned 
with the guidance and regulation of such processes 
genetically as well as epigenetically. Tissue- 
characteristic expression of glycosphingolipids has 
also been thought to be the outcome of such 
regulated biosynthetic processes. However, in 
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cancer, unregulated metabolism of glycosphin- 
golipids, such as the expression of glycosphin- 
golipids characteristic of the fetal stage, is 
frequently observed. Although the molecular 
mechanism and biological significance of the shift 
in the metabolism incancer cells to that in the fetal 
stage are not entirely clear,, precise analysis of the 
mode of glycosphingolipid expression in cells in 
the fetal, adult and cancerous stages may provide 
valuable information for understanding this 
phenomenon. To characterize the glycosphin- 
golipids in the human fetal stage, meconium has 
been shown to be a useful material. By utilizing 
two monoclonal antibodies, directed towards the 
Lc4Cer and NeuAca2-6Gal structures, respec- 
tively, we were able to demonstrate th  occurrence 
of distinctly different pathways in the human fetal 
stage for the synthesis of gangliosides with the 
same carbohydrate s quences. 
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2. MATERIALS  AND METHODS 
2.1. Glycosphingolipids from human meconium 
Extraction of total lipids from human meconium (A and O 
donors), followed by fractionation i to neutral and acidic lipids 
by DEAE-Sephadex (A-25, acetate form) column 
chromatography, was carried out as described previously [1,2]. 
The acidic glycosphingolipids were prepared from the acidic 
fraction by saponification and dialysis, and then purified by 
ganglioside-mapping [3] and high-performance liquid 
chromatography (HPLC) on a column (2 cm internal diameter 
x 25 cm) packed with Iatrobeads (6RS8010). Mono- 
sialogangliosides were eluted fromthe HPLC column with a 
linear gradient prepared from chloroform/methanol/water 
(55:45:2 and 20:80:2, by vol.) and monitored by TLC- 
immunostaining with monoclonal ntibodies. 
2.2. TLC-immunostaining 
A mouse monoclonal antibody, Y916 (IgM), to the 
NeuAcc~2-6Gal structure was obtained by immunizing mice 
(Balb/c) [5] with the total gangliosides from bovine milk fat 
globule membranes [6] and then hybridizing the sensitized lym- 
phocytes with mouse myeloma cells (SP2), and a human 
monoclonal ntibody, HMST-I (IgM), to Lc4Cer by hybridiz- 
ing the lymphocytes from a patient with uterine ndometrial 
adenocarcinoma with mouse myeloma cells (P3X63AgSUI). 
Gangliosides from human meconium were chromatographed on 
a thin-layer plate (Polygram; Macherey-Nagel, Duren, FRG) 
with a solvent system of chloroform/methanol/0.5o70 calcium 
chloride in water (55:45 : 10, by vol.). The plate was incubated 
with the blocking buffer (1 °T0 polyvinylpyrrolidone (PVP), I o7o 
ovalbumin and 0.02% NaN3 in phosphate-buffered saline 
(PBS)) at 37°C for 1 h, followed by about 120 ng protein of the 
monoclonal ntibody to NeuAcot2-6Gal in 3°70 PVP in PBS at 
37°C for 2 h. For the reaction with the monoclonal antibody 
against Lc4Cer, the plate was treated with 200 mU sialidase 
( Vibrio cholerae; Calbiochem-Behring, FRG) in 7 ml of PBS at 
37°C for 2 h prior to the blocking step. After washing the plate 
5 times with 0.1070 Tween 20 in PBS, the antibody bound on the 
TLC plate was detected with peroxidase-conjugated anti-mouse 
IgM (Cappel Lab., Cochraville, PA, USA) and anti-human 
lgM (Cappel Lab.) antisera for mouse and human monoclonal 
antibodies, respectively, and the enzyme substrates (H202 and 
4-chloro-l-naphthol) as described [4]. 
2.3. Structural determination f gangliosides 
The structures of the purified gangliosides were determined 
by TLC-immunostaining, exoglycosidase treatments and 
permethylation a alysis [4,6]. The exoglycosidases used were 
sialidase, B-galactosidases (S. pneumoniae nd jack bean, 
Sigma) and N-acetyl-/~-D-glucosaminidases (bovine kidney, 
Boehringer Mannheim; and jack bean, Sigma). 
3. RESULTS 
3.1. Acidic glycosphingolipids of human 
meconium 
As shown in fig.1 and as already reported [7], 
sulfat ide was present in the highest concentrat ion 
in human meconium, and the concentrat ion varied 
among individual specimens. The mean value for 
20 individuals was 54.24/zmol /g dry wt; this was 
13 times higher than that of  GM3 (4.03/~mol/g dry 
wt), which comprised about  85°70 of  the total  
gangliosides. Surprisingly, the concentrat ion of  
sulfatide in human meconium was higher than that 
o f  phosphol ip ids (6.39/zmol /g dry wt), the molar  
rat io of  phosphol ip ids,  cholesterol and sulfatide 
being 1.0: 10.4: 8.5, Thus, glycosphingol ipids,  par- 
t icularly sulfatide, are signif icantly accumulated in 
human meconium. 
3.2. TLC-immunostaining of  acidic glycosphingo- 
iipids from human meconium 
As shown in f ig . l ,  the total  human meconium 
acidic glycosphingol ipids,  corresponding to 20/zg 
o f  GM3-sial ic acid, were subjected to TLC and 
detected with orcinol  reagent (A), the monoclonal  
ant ibody to NeuAccr2-6Gal  (B) and the 
monoc lonal  ant ibody to Lc4Cer after neu- 
raminidase treatment o f  the plate (C), respectively. 
The gangl ioside (ganglioside 2), which migrated to 
a posit ion below that of  standard 
IV3NeuAcnLc4Cer f rom human erythrocytes on 
TLC and which was present in a concentrat ion of  
448 nmol /g  dry wt of  human meconium, was 
posit ively stained with the monoc lonal  ant ibody to 
NeuAca2-6Ga l .  When the plate was first treated 
with sial idase and then examined for reactivity 
with the monoc lonal  ant ibody to Lc4Cer, a posit ive 
spot (ganglioside 1), which, however, was not 
observable with orcinol  reagent, was clearly 
detected between GM3,  the largest ganglioside, 
and the second largest gangl ioside (ganglioside 2). 
It was clear that the gangl ioside with 
NeuAccr2-6Gal  was negative with the monoclonal  
ant ibody to Lc4Cer after sial idase treatment of  the 
plate. 
3.3. Structures of the gangliosides detected with 
monoclonal antibodies 
By monitor ing the reactivities of  gangliosides 
with the monoc lonal  ant ibodies to NeuAca~2-6Gal 
and Lc4Cer, two gangliosides were isolated, as 
shown in fig. 1. Gangl ios ide 1, which did not react 
with the monoc lonal  ant ibody to NeuAca2-6Ga l  
but reacted with the monoc lonal  ant ibody to 
Lc4Cer after sial idase treatment,  migrated to a 
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Fig.l. TLC of total acidic glycosphingolipids (T), and isolated gangliosides l and 2 from human meconium. Total acidic 
glycosphingolipids, corresponding to 20/~g of GM3-sialic acid, and gangliosides 1 and 2, corresponding to 5/Lg and l0/~g of sialic 
acid, respectively, were applied on a TLC plate and then developed with chloroform/methanol/0.5% calcium chloride in water 
(55 : 45 : 10, by vol.). After cutting the plate, the spots were detected with orcinol reagent (A), and by TLC-immunostaining with the 
monoclonal antibody to NeuAca2-6Gal (B) and the monoclonal antibody to Lc4Cer after treatment of he plate with V. cholerae 
sialidase (C). The major acidic glycosphingolipids migrating to above GM3 was sulfatide. The arrow indicates the position fstandard 
IV3NeuAcnLc4Cer from human erythrocytes. 
position similar to that of standard IV 3 
NeuAcnLc4Cer from human erythrocytes, and its 
concentration i human meconium was 18 nmol/g 
dry wt. Ganglioside 2, the second largest 
ganglioside in human meconium, migrated to a 
position lower than that of IV3NeuAcnLc4Cer on 
TLC and reacted with the monoclonal antibody to 
NeuAca2-6Gal  but did not react with the 
monoclonal antibody to Lc4Cer after sialidase 
treatment. Both gangliosides 1 and 2 were suscepti- 
ble to F. cholerae sialidase, which caused the 
release of N-acetylneuraminic a id as a sole sialic 
acid, and the products migrated on TLC to the 
same positions as Lc4Cer and nLc~Cer. However, 
although the asialo derivative of ganglioside 1 was 
identified as Lc4Cer with the respective 
monoclonal antibody, ganglioside 2 was again con- 
firmed to contain no Lc4Cer at all. Jack bean/3- 
galactosidase completely cleaved both asialo- 
gangliosides 1 and 2 to form trihexaosyl ceramides, 
but S. pneumoniae /3-galactosidase, which 
specifically reacts with/31-4 linkages but not with 
/5'1-3 linkages [8], only cleaved asialoganglioside 2 
completely. These results indicate that the 
nonreducing terminals of asialogangliosides 1 and 
2 are /3-galactose, and that of ganglioside 2 is 
linked only through a/31-4 linkage, which is not 
present in asialoganglioside 1. The trihexaosyl 
ceramides obtained from asialogangliosides 1 and 
2 on treatment with jack bean/3-galactosidase were 
cleaved sequentially with N-acetyl-~'-gluco- 
saminidase, followed by/3-galactosidase, and the 
final products were identified as glucosyl cera- 
mides, indicating that gangliosides I and 2 have the 
same carbohydrate s quence, NeuAc-Gal-GlcNAc- 
Gal-Glc-ceramide. On permethylation analysis, as 
shown in fig.2, ganglioside 2 gave 1,4,5-tri-O-ace- 
tyl-2,3,6-tri-O-methyl glucitol, 1,3,5-tri-O-acetyl- 
2,4,6-tri-O-methyl galactitol and 1,3,5-tri-O-acetyl- 
2-deoxy-2-methylacetamido-4,6-di-O-methyl gluci- 
tol in the ratio of 1:2:1. Thus, the structure of 
ganglioside 1 was concluded to be NeuAca~2- 
3GalB1-3GlcNAc4~l-3GalBI-4Glc4~l- lceramide, 
IV3NeuAcLc4Cer. On the other hand, 1,4,5-tri-O- 
acetyl-2,3,6-tri-O-methyl glucitol, 1,3,5-tri-O- 
acetyl-2,4,6-tri-O-methyl galactitol, 1,5,6-tri-O- 
acetyl-2,3,4-tri-O-methyl galactitol and 1,4,5-tri- 
O- acetyl- 2- deoxy- 2- methylacetamido- 3,6- di- O- 
methyl glucitol were obtained from ganglioside 2
in the ratio of 1 : 1 • 1 : 1 (fig.2). This indicates that 
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Fig.2. GLC of the partially methylated aidohexitoi acetates 
derived from gangliosides 1 and 2. The GLC columns for the 
left and right chromatograms contained 3070 ECNSS-M on 
Chromosorb W (100-200 mesh) and 2070 OV-17 on Celite 545 
(100-120 mesh), respectively. The scale indicates the retention 
time (rain). 
the structure of ganglioside 2 is NeuAc~2-6- 
Gald1-4GlcNAcdl - 3Galdl - 4G1c431 - lceramide, 
IV6NeuAcnLc4Cer. As a result, gangliosides with 
lacto-series type 1 and 2 chains in human meco- 
nium were found to be sialylated selectively at 
~z2-3 and ~z2-6 linkages, respectively, and mixed 
structures such as IV3NeuAcnLc4Cer and 
IV6NeuAcLc4Cer could not be entirely detected 
by chemical and immunochemical procedures. 
The concentrations of IV6NeuAcnLc4Cer and 
IV3NeuAcLc4Cer, as determined by TLC den- 
sitometry, were 448 and 18 nmol/g dry wt of 
human meconium. 
4. DISCUSSION 
As dearly shown in this communication, 
gangliosides with lacto-series type 1 and 2 chains in 
human meconium are sialylated at different 
linkages. The monoclonal antibody to Neu- 
Aca2-6Gal reacted with a single molecule, which 
was the second largest ganglioside in human 
meconium and which did not contain type 1 chain, 
even in a trace amount. Also, the molecule show- 
ing a positive reaction with the monoclonal an- 
tibody to Lc4Cer and migrating to within the 
region of sialyltetrahexaosyl ceramides was com- 
pletely negative with the monoclonal antibody to 
NeuAca2-6Gal. Therefore, mixed forms of the 
molecules, with respect o the sialic acid linkages 
and the asialocarbohydrate structures, that is, 
IV3NeuAcnLc4Cer and IV6NeuAcLc4Cer, were 
not present in human meconium. Probably due to 
the difference in the specificities of the sialidases 
used for TLC detection of Lc4Cer, we might not 
have been able to detect III6NeuAcLc4Cer, which 
was reported previously in human meconium [9]. 
Although IV6NeuAcnLc4Cer was detected as a 
minor component in normal adult human 
erythrocytes, liver and spleen [10,11], its synthesis 
is characteristically activated in human colorectal 
and lung carcinomas, which leads to cancer- 
associated antigenicity [12,13]. In addition, 
Lc4Cer, particularly in the sialylated form with an 
o~2-3 linkage, was shown to be highly accumulated 
in several human cancers including teratocar- 
cinomas [14] (Iwamori et al., unpublished). The 
two lacto-series gangliosides with the same car- 
bohydrate sequences in human meconium are on- 
cofetal antigens. Since IV3NeuAcnLc4Cer is 
frequently observed in adult human tissues and 
cells, our finding of the occurrence of 
IV6NeuAcnLc4Cer and IV3NeuAcLc4Cer in 
meconium indicates that a metabolic shift to for- 
mation of different linkages occurs developmental- 
ly, which may reflect the alteration of glycosyl 
transferases with different substrate specificities 
responsible for the synthesis of facto-series 
gangliosides. Analysis of the enzyme kinetics for 
the lacto-series gangliosides in combination with 
the sensitive detection with monoclonal ntibodies 
should shed light on the functional significance of 
the programmed expression of cell surface 
glycoconjugates and the underlying molecular 
mechanisms. 
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